News

Anat Loewenstein, MD, president of EURETINA, announces the EURETINA Innovation Spotlight (EIS) will return on September 3 this year.

Leading companies to unveil new research on retinal diseases at EURETINA 2025, showcasing innovative therapies and clinical trial results.

AMD treatment may become unrecogniable as gene therapies evolve.

identifeye HEALTH unveils a retinal screening platform, enhancing accessibility and efficiency in patient care through innovative technology and AI integration.

The committee will work to help the organization increase awareness and early identification of diabetes-related eye diseases and improve access to eye care treatment, policy development, research, and surveillance.

Catch up on this week's highlights in retina.

FDA issues a complete response letter to Outlook Therapeutics for ONS-5010, citing insufficient evidence of effectiveness for wet AMD treatment.

Researchers used adaptive optics scanning light ophthalmoscopy (AOSLO) to study retinas in mice with photoreceptor damage, specifically photoreceptor laser injury.

Advanz Pharma and Alvotech announced AVT06, a biosimilar to Eylea, was approved for neovascular age-related macular degeneration.

Fovea-sparing, multifocal, and bilateral lesions exhibited the fastest growth rates.

Included is the supplemental Biologics License Application (sBLA) for EYLEA HD seeking approval for both the treatment of macular edema following retinal vein occlusion (RVO) and the broadening of the dosing schedule to include every 4-week dosing across approved indications.

At the 2025 EURETINA Congress, keep an eye out for 11 editorial advisory board members from Modern Retina, Ophthalmology Times and Ophthalmology Times Europe.

Long-term cannabis use may reduce the risk of proliferative vitreoretinopathy after retinal detachment surgery, suggesting potential therapeutic benefits.

Revisiting a classic tool that still gets you out of a jam works best when you understand its powers and limitations.

Retina specialists will celebrate the major anniversary this September in Paris, France.

Kriya is developing gene therapies targeting chronic diseases such as geographic atrophy, trigeminal neuralgia, and type 1 diabetes.

A study reveals significant treatment burdens for patients with AMD and DME, highlighting the need for improved education and support to enhance outcomes.

Catch up on this week's highlights in retina.

Research reveals a significant link between androgen exposure and central serous chorioretinopathy, aiding clinicians in assessing patient risk factors effectively.

Research reveals that GLP-1 medications, including semaglutide, do not increase diabetic retinopathy risks, offering reassurance for patients and prescribers.

Research reveals how neighborhood social factors impact patients with tractional retinal detachments, highlighting the need for improved access to care and support.

Reliable visualization tools, especially those indicated for ocular use, are crucial for success.

Best disease, or vitelliform macular dystrophy, is a rare, inherited retinal condition causing macular degeneration by mutations in the BEST1 gene, leading to progressive vision loss and, in some cases, blindness.

jCyte initiates patient dosing in a new trial for famzeretcel, aiming to transform treatment options for retinitis pigmentosa.